QU496 - Provision of Cost Benefit Analysis of Carrier Screening for Genetic Disorders - AWARD

Birmingham City CouncilcontractContracts FinderRef QU496 - AWARDSME suitablecomplete
View buyer

Estimated value

Awarded value

£60k

Awarded 17 Oct 2021

Suppliers

1

Lots

1

1 awarded

Published

18 Oct 2021

Deadline 03 Sept 2021

Description

Birmingham City Council requires a supplier for the provision of a Desk Based Report on the Cost Benefit Analysis (CBA) of Genetic Autosomal Recessive Screening. This will be used to inform the action plan of the Birmingham Perinatal and Infant Mortality Strategy. We would like the report to include an estimate of service costs regarding stillbirths, perinatal mortality, infant mortality and lifetime associated with those that survive infancy. Costs can be based on historic service models in addition the estimates for the thresholds of cost effectiveness for each of the above. The costs should be specified for the NHS, social services and the wider costs to society. For the purposes of developing our Peri-natal and Infant Mortality Strategy, Birmingham City Council (BCC) Public Health requires an evaluation that compares the cost of screening for autosomal recessive conditions with the economic benefits accruing from changes in the prevalence rates of stillbirths, peri-natal and infant mortality and health outcomes. The cost benefits should include the financial savings to services in the health, social care and education sectors and the wider society. The CBA needs to be based on provision of screening women who are planning a pregnancy and the women and partners who are considered to be at risk from a genetic disorder with X-linked genetic conditions with a panel screening for multiple conditions. The CBA needs to consider a Genetic Counselling component and the cost considerations for this element. Your proposal must: o Describe your methodology for writing this report to include planning, mapping, modelling and reporting o Provide a breakdown of total costs including key expenditure anticipated to deliver the project The contract to undertake the CBA of autosomal recessive screening will be for a period of 6 months commencing 13th September 2021. The Council will be using its free to use e-tendering system (in-tend) for the administration of this procurement process and potential suppliers must register with the system to be able to express an interest. If you wish to express an interest in this opportunity please click on the following link to access https://in-tendhost.co.uk/birminghamcc/ and submit your details to register. You will then be sent details on how to log on which will enable you to download all relevant tender documentation. If you are unable to register with In-tend or have any questions or problems on how to use this web site please either email us at: cps@birmingham.gov.uk or call CPS Helpdesk on 0121 464 8000. Your completed tender submission should be returned by noon on 3rd September 2021 via the 'in-tend' system https://in-tendhost.co.uk/birminghamcc

Scope

Reference
QU496 - AWARD
Commercial tool
Standalone contract
Contract dates
18 Oct 2021 to 18 Apr 2022
CPV classifications
71620000 72316000 85144000 85147000 85323000
Particular suitability
Small and medium-sized enterprises (SME)

Submission & procedure

Submission deadline
03 Sept 2021, 11:00 am

Award details

Awarded supplier(s), contract period and value as published in the award notice.

Awarded value

£60k

Award date

17 Oct 2021

Contract start

18 Oct 2021

Contract end

18 Apr 2022

Awarded to